Current challenges in the treatment of gliomas: The molecular era DOI

Castalia Fernández,

Juan Zafra, Felipe Couñago

et al.

World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(8), P. 982 - 986

Published: Aug. 16, 2024

Gliomas originate from glial cells in the central nervous system. Approximately 80%-85% of malignant brain tumors adults are gliomas. The most common system tumor children is low-grade pediatric glioma. Diagnosis was determined by histological features until 2016 when World Health Organization classification integrated molecular data with anatomopathological information to achieve a more integral diagnosis. Molecular characterization has led better diagnostic and prognostic staging, which turn increased precision treatment. Current efforts focused on effective therapies prolong survival improve quality life adult patients However, improvements have been modest. Currently, clinical guidelines, as well article Mohamed

Language: Английский

Nanotechnology as a new strategy for the diagnosis and treatment of gliomas DOI Creative Commons
Jun Lei,

Yiyang Huang,

Yichuan Zhao

et al.

Journal of Cancer, Journal Year: 2024, Volume and Issue: 15(14), P. 4643 - 4655

Published: Jan. 1, 2024

Glioma is the most common malignant tumor of central nervous system (CNS), and characterized by high aggressiveness a recurrence rate.Currently, main treatments for gliomas include surgical resection, temozolomide chemotherapy radiotherapy.However, prognosis glioma patients after active standardized treatment still poor, especially glioblastoma (GBM); median survival only 14.6 months, 5-year rate 4-5%.The current challenges in difficulty complete poor blood-brain barrier (BBB) drug permeability, therapeutic resistance, tumor-specific targeting.In recent years, rapid development nanotechnology has provided new directions diagnosing treating gliomas.Nanoparticles (NPs) are excellent surface tunability, precise targeting, biocompatibility, safety.In addition, NPs can be used gene therapy, photodynamic antiangiogenic therapy combined with biomaterials thermotherapy.In decades, breakthroughs have been made various functional NPs, expected to become strategy diagnosis treatment.In this paper, we review obstacles discuss potential latest glioma.

Language: Английский

Citations

4
Deciphering the role of non-coding RNAs SNHG18, HOXA11-AS, MEG3, and MDC1-AS1 in glioma patients: A combined experimental and computational study DOI
Kamal Mohammadian, Arash Moradi,

Mansoureh Shabani

et al.

Gene Reports, Journal Year: 2024, Volume and Issue: 36, P. 101973 - 101973

Published: July 14, 2024

Language: Английский

Citations

2
Metabolism: an important player in glioma survival and development DOI Creative Commons
Ning Wang, Yiru Yuan, Tianhao Hu

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Oct. 22, 2024

Gliomas are malignant tumors originating from both neuroglial cells and neural stem cells. The involvement of contributes to the tumor's heterogeneity, affecting its metabolic features, development, response therapy. This review provides a brief introduction importance metabolism in gliomas before systematically categorizing them into specific groups based on their histological molecular genetic markers. Metabolism plays critical role glioma biology, as tumor rely heavily altered pathways support rapid growth, survival, progression. Dysregulated processes, involving carbohydrates, lipids, amino acids not only fuel development but also contribute therapy resistance metastatic potential. By understanding these changes, key intervention points, such mutations genes like RTK, EGFR, RAS, IDH can be identified, paving way for novel therapeutic strategies. emphasizes connection between clinical challenges, offering actionable insights future research gliomas.

Language: Английский

Citations

2
Current challenges in the treatment of gliomas: The molecular era DOI

Castalia Fernández,

Juan Zafra, Felipe Couñago

et al.

World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(8), P. 982 - 986

Published: Aug. 16, 2024

Gliomas originate from glial cells in the central nervous system. Approximately 80%-85% of malignant brain tumors adults are gliomas. The most common system tumor children is low-grade pediatric glioma. Diagnosis was determined by histological features until 2016 when World Health Organization classification integrated molecular data with anatomopathological information to achieve a more integral diagnosis. Molecular characterization has led better diagnostic and prognostic staging, which turn increased precision treatment. Current efforts focused on effective therapies prolong survival improve quality life adult patients However, improvements have been modest. Currently, clinical guidelines, as well article Mohamed

Language: Английский

Citations

0